Technology offer : Leptospirosis Rapid Diagnostic Test

Technology's description

Leptospirosis is a growing public health concern in many tropical and subtropical countries. However, its diagnosis is difficult because of non-specific symptoms and concurrent other endemic diseases. In many regions the laboratory diagnosis is not available due to a lack of preparedness and simple diagnostic assay or difficult access to references laboratories.

The technology developed within the Pasteur Institute refers to the use of a new antigen for the detection of anti-leptospira human IgM. The technology has been developed in ELISA and Vertical flow rapid diagnostic test (RDT). First tries gives for ELISA a sensitivity of 94% and specificity of 99%, and the RDT shows a sensitivity of 90% and specificity of 94%. 



Advantages

  • Field adapted diagnostic
  • Few final products can be developed from this technology
  • Major public health concern in many regions
  • Pasteur Institute developing laboratory : National Reference Center for leptospirosis, and WHO Collaborating Center
  • Can be used as a differential diagnosis
Ref : OT-00107

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Rapid Diagnostic Test and ELISA kit

Intellectual property

  • Patent

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27